We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.
Precision genome editing
Our next-generation CRISPR genome-editing technology enables superior specificity and precision. Our patented chRDNA (CRISPR hybrid RNA-DNA) technology drives for complex genome editing, including multiplex gene knockout and insertion, while maintaining genomic integrity.
Off-the-shelf cell therapies
We are developing allogeneic, or off-the-shelf, CAR-T cell therapies from healthy donor cells to address the limitations of currently approved therapies.
Armored for enhanced activity
We believe armoring is the key to unlocking the full potential of allogeneic cell therapies. We use our chRDNA technologies to armor our cell therapies through multiple genome-editing strategies, including checkpoint disruption, immune cloaking, or a combination of these two strategies, to enhance activity against devastating diseases.
“Caribou is a leader in the CRISPR field, successfully leveraging its proprietary genome-editing technologies to develop allogeneic cell therapies that are potentially transformative for patients.”
Jennifer Doudna, PhD
Co-founder of Caribou
Co-recipient of the 2020 Nobel Prize in Chemistry
Join the Herd
Caribou Biosciences is a pioneer in genome editing and cell therapy development, and we are seeking talented and passionate individuals to join our team.
